Life sciences company Agilent Technologies Inc. said Thursday it has agreed to acquire privately held BioTek Instruments for $1.165 billion. Including expected tax benefits, the company expects to pay about $1.05 billion, Agilent said in a statement. BioTek specializes in plate readers and imaging systems and generated revenue of $162 million fiscal 2018 to end December. Revenue is expected to grow about 10% in 2019. The deal is expected to close in Agilent's fiscal fourth quarter and to add 2 cents to 4 cents to fiscal 2020 non-GAAP per-share earnings. Agilent shares rose 0.6% premarket and have gained about 9% in 2019, while the S&P 500 has gained 19%.